Incapacitating solar urticaria: successful treatment with omalizumab
An. bras. dermatol
;
94(3): 331-333, May-June 2019. graf
Article
in English
| LILACS
| ID: biblio-1011115
ABSTRACT
Abstract Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Hereby, we report a case of solar urticaria refractory to conventional treatment strategies, with an excellent response to treatment with omalizumab and phototesting normalization.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Sunlight
/
Urticaria
/
Anti-Allergic Agents
/
Omalizumab
Type of study:
Diagnostic study
/
Etiology study
Limits:
Humans
/
Male
Language:
English
Journal:
An. bras. dermatol
Journal subject:
Dermatology
Year:
2019
Type:
Article
Affiliation country:
Portugal
Institution/Affiliation country:
Centro Hospitalar de Leiria/PT
Similar
MEDLINE
...
LILACS
LIS